Vaxcyte Inc. (PCVX) is a clinical-stage biotechnology company focused on developing and commercializing vaccines to prevent or treat infectious diseases. The company's platform technology, known as VAXCYTE, allows for the efficient design and production of complex protein-based vaccines that can elicit a broad and durable immune response.
Vaxcyte's lead product candidate is VAX-24, a 24-valent pneumococcal conjugate vaccine that targets a range of pneumococcal strains responsible for invasive pneumococcal disease (IPD), including pneumococcal pneumonia and meningitis. The company is also developing a vaccine candidate for group A streptococcus (GAS), which can cause a range of illnesses, from minor skin infections to life-threatening conditions such as necrotizing fasciitis and toxic shock syndrome.
In addition to its vaccine development efforts, Vaxcyte is exploring partnerships with other companies in the biopharmaceutical industry to leverage its VAXCYTE technology platform for the development of new vaccines targeting other infectious diseases.
|
